Concepedia

Author

Christine DiRienzo

Pfizer (United States)

Also Known As

C.G. DiRienzo, Christine DiRienzo, Christine Dirienzo, Christine G DiRienzo, Christine G. DiRienzo, Christine Gabriella DiRienzo

15

Publications

330

Citations

8

H-Index

22

Concepts

All Affiliations

Pfizer (United States)Cornell UniversityUniversity of California, Los AngelesGenmab (Denmark)GlaxoSmithKline (United States)
CD

About

Christine DiRienzo is an author at Pfizer (United States) specializing in medicine, cell transplantation, and immunology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

4

4

91

2

Immunology

2

2

24

3

Health Sciences

1

1

11

4

Allergy

1

1

13

5

Pathology

1

1

41

Christine DiRienzo

×

8

Publications

310

Citations

8

H-Index

YearCitations

Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study

Myron S. Czuczman, Luis Fayad, Vincent Delwail,

Blood

2012

125

Glasdegib Plus Intensive/Nonintensive Chemotherapy in Untreated Acute Myeloid Leukemia: BRIGHT AML 1019 Phase III Trials

Jörge E. Cortes, Hervé Dombret, Akil Merchant,

Future Oncology

2019

42

Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study

Richard R. Furman, Herbert Eradat, Christine DiRienzo,

The Lancet Haematology

2016

41

A Phase II Trial of Ofatumumab in Subjects with Waldenstrom's Macroglobulinemia,

Richard R. Furman, Herbert Eradat, Christine DiRienzo,

Blood

2011

28

Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib

Aaron T. Gerds, Tetsuzo Tauchi, Ellen K. Ritchie,

Leukemia Research

2019

26

Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial

Mikkael A. Sekeres, Pau Montesinos, Jan Novák,

Leukemia

2023

24

T-Cell Receptor Vα Spectratype Analysis of a CD4-Mediated T-Cell Response against Minor Histocompatibility Antigens Involved in Severe Graft-versus-Host Disease

Christine DiRienzo, Gëorge F. Murphy, Stephen C. Jones,

Biology of Blood and Marrow Transplantation

2006

13

MagnetisMM-6: An open-label, multicenter, randomized phase 3 study of elranatamab + daratumumab + lenalidomide (EDR) versus daratumumab + lenalidomide + dexamethasone (DRd) in transplant ineligible (TI) patients with newly diagnosed multiple myeloma (NDMM).

Sebastian Grosicki, Su‐Peng Yeh, Jeffrey Huang,

Journal of Clinical Oncology

2023

11

Page 1